Mehrdad Ghaffari, MD
Sleep Medicine · Altoona, PANPI 1770700718
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,243 of the $2,826 with a category attached, or 79.4%. 8 manufacturers reported payments, led by Pulmonx Corporation at 47.5% of the total. Reporting peaked in 2023 at $1,362 and has fallen 86.8% since, to $179 in 2025.
Across 29 payments — averaging $97.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- Johnson & Johnson$1K
- Genentech USA, Inc.$80
- Curonix LLC$64
- United Therapeutics Corporation$43
- GSK$19
- plus $32 from 2 others
What the payments were for
- Travel & lodging$2,24379%
- Food & beverage$44316%
- Education$1405%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 2 | $1,343 |
| Johnson & Johnson | 11 | $1,244 |
| Genentech USA, Inc. | 2 | $80 |
| Curonix LLC | 1 | $64 |
| United Therapeutics Corporation | 10 | $43 |
| GSK | 1 | $19 |
| Insmed, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$1,343
- PULMONX CHARTIS TABLET CONSOLE$1,343
- CHARTIS CATHETER$1,343
- ZEPHYR DELIVERY CATHETER$1,343
- Monarch Platform$1,150
How this compares
$2,826 in reported general payments places this provider in the 75th percentile of 87 sleep medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 993 | $671,791 |
| OfevNintedanib Esylate | 47 | $553,724 |
| HetliozTasimelteon | 11 | $246,709 |
| Pirfenidone | 31 | $209,218 |
| Breo ElliptaFluticasone/Vilanterol | 432 | $199,550 |
| Fasenra PenBenralizumab | 12 | $66,214 |
| Spiriva RespimatTiotropium Bromide | 120 | $63,782 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 89 | $42,678 |
| Advair HfaFluticasone Propion/Salmeterol | 74 | $26,219 |
| EliquisApixaban | 32 | $22,348 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 177 | $21,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 324 | $10,427 |
| Arnuity ElliptaFluticasone Furoate | 34 | $9,535 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $8,508 |
| Atrovent HfaIpratropium Bromide | 16 | $8,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $19 | $930,9481,568 claims |
| Johnson & JohnsonXarelto | $1,244 | $6,22712 claims |
| AstraZenecaPulmicort Flexhaler | $14 | $2,25311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 87 sleep medicine providers in Pennsylvania.
Other sleep medicine in Altoona
- Chandra Matadeen-AliGlen Mills$2.3M
- Pratima BehariCamp Hill$108K
- Olufunke Afolabi-BrownHorsham$93K
- Karl DoghramjiPhiladelphia$85K
- Richard SchwabPhiladelphia$81K
- Ralph GalloWynnewood$80K
- Gaurav PatelMedia$45K
- Maria SunseriPittsburgh$23K
- Michael WeinsteinLansdale$18K
- Nalaka GooneratnePhiladelphia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.